Clinical Trial Update: Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating 2 mg intravitreal aflibercept with different dosing schedules for wet age-related macular degeneration over 2 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2020-05-21